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Abstract
Background: The β-lactam antibiotics have traditionally been the main treatment of Enterobacteriaceae infections,
nonetheless, the emergence of species producing β- Lactamases has rendered this class of antibiotics largely
ineffective. There are no published data on etiology of urinary tract infections (UTI) and antimicrobial resistance
profile of uropathogens among children in Qatar. The aim of this study is to determine the phenotypic and
genotypic profiles of antimicrobial resistant Enterobacteriaceae among children with UTI in Qatar.
Methods: Bacteria were isolated from 727 urine positive cultures, collected from children with UTI between
February and June 2017 at the Pediatric Emergency Center, Doha, Qatar. Isolated bacteria were tested for
antibiotic susceptibility against sixteen clinically relevant antibiotics using phoenix and Double Disc Synergy
Test (DDST) for confirmation of extended-spectrum beta-lactamase (ESBL) production. Existence of genes
encoding ESBL production were identified using polymerase chain reaction (PCR). Statistical analysis was done
using non-parametric Kappa statistics, Pearson chi-square test and Jacquard’s coefficient.
Results: 201 (31.7%) of samples were confirmed as Extended Spectrum β -Lactamases (ESBL) Producing
Enterobacteriaceae. The most dominant pathogen was E. coli 166 (83%) followed by K. pneumoniae 22 (11%). Resistance
was mostly encoded by bla CTX-M (59%) genes, primarily bla CTX-MG1 (89.2%) followed by bla CTX-MG9 (7.7%). 37% of
isolated bacteria were harboring multiple bla genes (2 genes or more). E. coli isolates were categorized into 11 clusters,
while K. pneoumoniae were grouped into five clonal clusters according to the presence and absence of seven genes
namely bla TEM, bla SHV, bla CTX-MG1, bla CTX-MG2, bla CTX-MG8 bla CTX-MG9, bla CTX-MG25.
Conclusions: Our data indicates an escalated problem of ESBL in pediatrics with UTI, which mandates implementation
of regulatory programs to reduce the spread of ESBL producing Enterobacteriaceae in the community. The use of
cephalosporins, aminoglycosides (gentamicin) and trimethoprim/sulfamethoxazole is compromised in Qatar among
pediatric population with UTI, leaving carbapenems and amikacin as the therapeutic option for severe infections caused
by ESBL producers.
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β-lactamases (ESBLs) is a global concern that demands
global attention due to the limited available treatment
options [1–4]. Over the past two decades, there has been
an exponential increase in β-lactamase resistance world-
wide accompanied with a significant escalation in the
prevalence of ESBL-producing Enterobacteriaceae [5].
Unfortunately, ESBL-producing bacteria in children have
come to the forefront of emerging antibiotic-resistant bac-
teria worldwide [6]. β-lactamases are divided into four
functional groups: penicillinases, ESBLs, carbapenemases,
and AmpC-type cephalosporinases [7]. Specifically, ESBLs
is a group of plasmid-encoded enzymes that confer resist-
ance to third generation cephalosporins [8–10]. ESBLs are
divided into three groups according the encoding of TEM,
SHV and CTX-M genes [11, 12]. CTX-M enzymes are the
most common and are further classified into five major
phylogenetic groups based on gene sequences namely,
CTX-M -1, CTX-M-2, CTX-M-8, CTX-M-9, and
CTX-M-25 [11]. ESBL-producing Escherichia coli (E. coli)
and Klebsiella pneumoniae (K. pneumoniae) are the pre-
dominant organisms in childhood infections, and they
pose significant threat to human health [13]. These organ-
isms are listed among the pathogens for which there are
few potentially effective drugs [1]. About 57% of blood-
stream infections are caused by ESBL-producing Entero-
bacteriaceae, which are more likely to result in death
compared to the infections caused by a non
ESBL-producing strains [14].
Urinary Tract Infections (UTIs) continue to be one of
the most common cause of illness in young children
worldwide [9]. It distresses the child, concern the parent,
and may cause permanent renal sequelae. The β-lactam
antibiotics have traditionally been the main antibiotics
for treatment of infections caused by Enterobacteriaceae,
but the emergence of ESBL has rendered this class of
antibiotics largely ineffective. It is therefore important to
run epidemiological studies to define the epidemiology
and profiles of these resistant bacteria for its impact on
the development and implementation of stewardship
programs.
High prevalence of extended-spectrum-β-lactamase
(ESBL) and carbapenemase producing gram negative
bacteria (GNB) has been reported in the Arabian Penin-
sula [15]. Nonetheless, little is known about the preva-
lence and profile of these bacteria in pediatric
population [16] in the region. Prevalence of ESBL in
urine among pediatric population has been gradually in-
creasing in Qatar (HMC annual antibiogram). For ex-
ample, the percentage of E.coli ESBL producers have
gradually increased from 18% in 2010 to 24% in 2014,
and reached 31.7% in 2017 (January–June) as reported
in this study.
This is the first study that describes at the molecular
level the genotypic profile of ESBL producing bacteria
among children with UTIs in Qatar. Our data indicates
rapid increase in ESBL resistance among Enterobacteria-
ceae in pediatrics with UTI, which mandates rapid regu-
latory and monitoring reforms at the State level.
Methods
Clinical isolates and controls strains
Ethical approval for this study was obtained from the
Medical Research Centre (MRC), Hamad Medical
Corporation (HMC), Doha, Qatar, protocol no. 16434/
16. A total of 727 urine Samples were collected be-
tween February and June of 2107 from children (0–
15 years of age) hospitalized with lower UTI at the
Pediatric Emergency Center-HMC. All urine analysis
were performed on patients presented with symptoms,
mainly fever and dysuria. Urinary catheter was ap-
plied for all patients less than or equal 2 years of age,
cerebral palsy (CP) patients and patients under inter-
mittent catheterization. Otherwise, urine was obtained
from mid-stream catch. Samples that did not yield
significant bacterial growth, those that had multiple
organisms and samples with suspected contamination
as per lab report, were excluded from the study, and
no duplicate samples were collected. All of the re-
ported cases had UTI as their primary diagnosis. For
each patient, demographic data such as age, national-
ity, and gender were collected. Out of the above sam-
ples, 635 (87.3%) were positive for Enterobacteriaceae
species which were then isolated using readymade
Cystine Lactose Electrolyte-Deficient media (IMES,
Doha, Qatar). Isolated bacteria were identified by
MALDI-TOF (Bruker Daltonik GmbH, Leipzig,
Germany) and initial antimicrobial susceptibility test-
ing was performed by Phoenix using the NMIC/ID-5
panel (BD Biosciences, Heidelberg, Germany) accord-
ing to the manufacturer’s recommendations. Both au-
tomated tests were performed at Hamad General
Hospital Microbiology laboratory. All intermediate re-
sistant isolates were considered as susceptible. Initial
testing with Phoenix revealed 201 (31.7%) isolates as
Extended Spectrum β -Lactamases (ESBL) producer
Enterobacteriaceae. Susceptibility testing was done for
16 clinically relevant antibiotics. 110 of these samples
were randomly selected for further genotypic analysis.
Standard strains, E. coli ATCC® 25,922 and E. coli
ATCC® 35,218, were used as controls for antimicrobial
drug susceptibility testing. E. coli NCTC® 13,461™, E. coli
NCTC® 13,462™, E. coli NCTC ®13,463™, Enterobacter
cloacae NCTC ®13,464™ and K. pneumonia NCTC®
13,465™, E. coli ATCC® 35,218™ and E. coli NCTC
®13,368™ were used as positive controls, for CTX-M G1,
CTX-M G 2, CTX-M G 8, CTX-M G 9, CTX-M G25
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25, bla TEM and bla SHV, polymerase chain reaction
(PCR) assays, respectively.
ESBL phenotype confirmation
Isolates that were tested positive for ESBL by Phoenix
were consequently confirmed by Double Disc Synergy
Test (DDST) as previously described [17, 18]. Briefly, syn-
ergy was determined between a 20/10 μg disc of
amoxicillin-clavulanate (BD- Sensi Disc™) and 30-μg disc
of ceftazidime and ceftriaxone (BD- Sensi Disc™), placed
onto Mueller–Hinton agar (Oxoid Ltd., Basingstoke,
Hampshire, England) inoculated with a microbial suspen-
sion of 0.5 McFarland turbidity, at a distance of 15 mm
apart from the edge of the amoxicillin-clavulanate disc.
The cefoxitin (30 μg, BD- Sensi Disc™) disc was placed in
any available space remaining on the plate. Extension of
the edge of the exhibition zone by > 5 mm towards the
disc of amoxicillin-clavulanate disc, together with suscep-
tibility to cefoxitin was interpreted as positive for the
ESBL production [18].
Molecular genotyping of ESBL genes
DNA was extracted from bacterial cultures using
QIAamp® UCP pathogen mini Kit (Qiagen, Germany)
following manufacturer’s instructions. Extracted DNA
was then used to run PCR for seven genes and using
previously published primers [19, 20] . The conditions
used for blaTEM and blaSHV reactions were as follows:
PCR mixture was made in volume of 20 μl containing
0.5 μM of each primer, 50 ng DNA, 1× master mix (Hot
star Taq plus master mix (Qiagene, Germany)) and
DPEC H2O up to 20 μl. The reaction was amplified in
GeneAmp* PCR system 9700 thermocycler under the
following conditions: 1. Initial denaturation at 96 °C for
5 min.; 2. 32 cycles consisting of denaturation at 96 °C
for 30 s., annealing at 44 °C (bla TEM) and at 58 °C (bla
SHV) for 45 s, and extension for 60 s. at 72 °C; and 3. A
final extension cycles at 72 °C for 10 min. Multiplex
PCR (MPCR) was performed in a final volume of 30 μl
containing 0.23 μM of each primer (bla CTX-M-G(1,2,8,9
&25)), 50 ng DNA, 1× master mix (Hot star Taq plus
master mix (Qiagene, Germany) [19]) and DPEC H2O
up to 30 μl to screen for bla CTX-M- G (1,2,8,9 & 25)
genes. Amplified products were subjected to electro-
phoresis in 1.2% agarose (Agarose- LE, Ambion®, USA),
stained with ethidium bromide (Promega, Madison,
USA) and visualized using Bio-Rad gel doc system (Bio -
rad, Gel Doc tm XR System 170–8170, Canada).
Clustering of ESBL-positive isolates
An agglomerative hierarchical algorithm was used to de-
rive a cluster analysis dendrogram to establish the rela-
tionship between individual E. coli (n = 95) and
Klebsiella pneumoniae (n = 13) isolates based on the
presence and absence of 7 genes (blaTEM, blaSHV, bla
CTXM -G 1, bla CTXM -G2, bla CTXM -G8, bla CTXM
-G9 & bla CTXM –G25), whichare reported in the litera-
ture to encode for ESBL. The scores ‘1’ and ‘0’ were
given for the presence and absence of bands respectively
[21–23]. The data obtained by scoring of the genetic
profiles of different ESBL genes were subjected to cluster
analysis, and hierarchical cluster dendrogram was cre-
ated using Past software version 1.91 [24]. A similarity
matrix values were used for cluster analysis.
Data analysis
Data were introduced into Microsoft Excel 2010 (Micro-
soft Corporation, New York, USA) to generate figures
and run initial analysis and further statistical analysis
were done using SPSS statistics 24 (Statistical Package
for the Social Science; SPSS Inc., Chicago, IL, USA). Re-
lation between gene type and resistance of each anti-
biotic was cross-tabulated using non-parametric Kappa
statistics; on the other hand, relation between gene type,
nationality and age grouping was calculated using Pear-
son chi-square test. Probability value (P value) less than
0.05 was considered statistically significant. Past soft-
ware, version 1.91, was used to construct hierarchical
clustering dendrogram and Jacquard’s coefficient was ap-
plied to generate the similarity values for generation of
the cluster analysis [24].
Results
Demography of the study population
The demographic profile of the studied population is
summarized in Table 1. Sixteen percent (n = 34) of sam-
ples were collected from males compared to 83.% (n =
167) from females (0–15 years of age), with Male to fe-
male ratio of approximately 1:5. ESBL producing Entero-
bacteriaceae were more prevalent among Qataris 46
(22.8%), Egyptians 37 (18.4%), Indians 27 (13.4%), and to
lesser extent in Pakistani 21(10.4%). Most of the ESBL
Table 1 Demographic profile of the study population (n = 201)





Qatari Non Qatari (na=24)
Male 34 (16.9%) 5 (2.5%) 29 (14.42%)
Female 167(83%) 41 (20.4%) 126 (62.7%)
Total no./percentage 201 (100%) 46 (22.9%) 155 (77.11%)
Age group (years)
< 2 60 (29.9%) 7 (36.8%) 53 (26.4%)
2–5 82 (40.8%) 18 (9%) 64 (31.8%)
6–15 59 (29.4%) 20 (10%) 39 (19.4)
aRepresent the number of nationalities tested
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was detected among children between 0 and 5 years of
age, n = 142 (70.6%).
Etiology of ESBL-associated UTI infections
Out of 635 Enterobacteriaceae positive urine cultures,
201 (31.7%) were found to be ESBL producing bacteria.
E. coli species was the most prominent with prevalence
rate of 83% (n = 166), followed by Klebsiella pneumoniae
11% (n = 22) and the rest 6% included Citrobacter koseri,
Enterobacter cloacae, Serratia marcescens, Citrobacter
amalonaticus.
Phenotypic resistance profile of ESBL isolates
Antibiotics resistance profile of ESBL-producing patho-
gens is depicted in Fig. 1. All ESBL-producing isolates
showed 100% resistance to ampicillin, and to all cephalo-
sporins including cephalothin, cefazolin, ceftriaxone and
cefepime. Low resistance was recorded to carbapenems.
Resistance ranged between 2.5% to meropenem, ertape-
nem and 10% to imipenem. Among the β-lactam/β-lac-
tamase inhibitor combinations, 9% were resistant to
piperacillin/tazobactam, whereas 99% were resistant to
amoxicillin/clavulanic acid. Regarding aminoglycosides,
all the isolates were susceptible to amikacin, and 24.4%
of which were resistant to gentamicin. The resistance
prevalence to other classes of antibiotics namely, cefoxi-
tin, nitrofurantoin, trimethoprim/sulfamethoxazole and
ciprofloxacin was 19.4, 13, 59.7 and 36%, respectively.
Molecular genotyping profile of ESBL isolates
110 ESBL producing bacterial isolates representing 95 E.
coli, 13 K. Pneumonia, one Citrobacter koseri and one
Enterobacter cloacae were randomly selected and char-
acterized with PCR for genes encoding resistance (Fig. 2).
Of these, the highest resistance (n = 65, 59%) was
encoded by bla CTX-M genes: bla CTX-MG1 (89.2%), bla
CTX-MG9 (7.7%), and bla CTX-MG2 (0.9%) and bla
CTX-MG8 (1.5%). bla TEM and bla SHV genes were de-
tected in 2.7 and 0.9% of the isolates, respectively. 37.3%
of bacteria harbored multiple bla genes (≥ two genes).
Two bla genes were detected in 20 (18.2%) E. coli and 3
(3.2%) of K. pneoumoniae isolates. 77% of K. pneoumo-
niae and 6.3% of E. coli isolates were harboring three bla
genes. While majority of the ESBL E. coli resistance was
encoded by one gene, blaCTX-M-G1 58 (61.1%), resist-
ance in k. pneoumoniae isolates was encoded by blaSHV,
blaTEM and blaCTX-MG1 genes (46.2%) concurrently
(Fig. 3). blaCTX-M-G25 was not detected in any isolate.
Correlation between phenotypic and genotypic profiles
The antibiotic resistance outcomes (resistance or suscep-
tible [i.e., binary]) were cross- tabulated with the six de-
tected ESBL genes using kappa statistics (Table 2). A
significant association (p < 0.05) were found between the
presence of TEM, nitrofurantoin and trimethoprim/
sulfamethoxazole; SHV and nitrofurantoin; CTXM-G2
and piperacillin/tazobactam. The presence of individual
ESBL genes was not significantly different (P > 0.05,
Pearson Chi- square test) by nationality or age.
Clustering and similarity of ESBL-positive isolates
Cluster analysis was used to study similarity among indi-
vidual E.coli (n = 94) and K. pneumoniae (n = 13) isolates
Fig. 1 Antimicrobial resistance profile of 201 ESBL producing
bacteria isolated from children (age 0 to 15 years) with UTI. Isolates
were tested for antibiotics resistance against 16 clinically relevant
antibiotics using phoenix NMIC/ID-5 panel (BD Biosciences,
Heidelberg, Germany). The figure depicts the percentage of isolates
with resistance to each of the antibiotics. TZP: piperacillin/
tazobactam; SXT: trimethoprim/sulfamethoxazole; AMC:
Amoxicillin/clavulanic acid
Fig. 2 Detection of blaSHV, blaTEM and blaCTX-M-G (1,2,8,9, &25)
antibiotic resistance genes in 110 ESBL Enterobacteriaceae
pathogens isolated from children with UTIs. Representative samples
are shown. Multiplex PCR was performed for detection of CTX-M
groups while monoplex PCR was used for detection of TEM and
SHV. The amplification products of each isolate were run on the
same lane for detection of bla genes. Lane 1: blaTEM, blaSHV&
blaCTX-MG1; Lane 2: blaTEM, blaSHV & bla CTX-M-G1: Lane 3: blaCTXM-
G9; Lane 4: blaSHV & blaCTXM-G1; Lane 5: blaSHV; Lane6: blaCTX-MG1;
Lane 7: blaCTXM-G2; Lane 8; blaCTXM-G8, Lane 9: blaTEM &blaCTXM-
G8; Lane 10, bla TEM, blaSHV &blaCTXM-G8; Lane 11: blaSHV & blaCTXM-
G1; Lane 12: blaNCTC 13,351 E. coli Positive control for blaTEM, NCTC
13368 K. pneumonia positive control for blaSHV, NCTC 13461 E. coli
positive control for blaCTX-MG1: Lane 13: ATCC 25922 E. coli
negative control
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according to presence and absence of 7 genes (bla
TEM, bla SHV, bla CTXM -G 1, bla CTXM- G2, bla
CTXM G8, bla CTXM G9 & bla CTXM G25). The E.
coli positive isolates were distributed into one of the
three main branches A, B and C (Fig. 4a), then sub
grouped into 11 clusters (A1, A2, A3, A4 A5, B1, B2,
B3, B4, B5 and C1). Most of the E. coli isolates clus-
tered in A2 (61.7%) which includes only CTXM-G1
enzyme.Around 20.2% clustered in A5 (which includes
a combination of TEM and CTXM-G1 enzymes. On
the other hand, K. pneoumoniae were distributed into
one of the two main branches A and B (Fig. 4b), then
sub grouped into five clusters (A1, A2, B1, B2 and
B3), with the main cluster being B2 (46.2%) which
represent combination of TEM, SHV and CTXM-G1
type enzymes.
Discussion
Out of a 635 Enterobacteriaceae isolated from urine
samples obtained from a cohort of children with UTI,
201 (31.7%) were found to be ESBL. E. coli species was
the most prevalent representing 83% (n = 166) of the iso-
lates, followed by K. pneumoniae which represented 11%
(n = 22). This is in agreement with other studies includ-
ing a recent one from Sri Lanka [25] in which E. coli
and Klebsiella species represented 86.8 and 13.1% of
UTI infections among adult patients. Expectedly, ESBL
was more predominant among females than males with
a ratio of 4.9 to 1. It has been frequently reported thatU-
TIs occur far more frequently in girls than in boys dur-
ing the first few months of life, presumably due to the
shorter length of the female urethra [26, 27]. The most
affected group of our study were the children ranging in
Fig. 3 Distribution of bla genes among ESBL Enterobacteriaceae obtained from urine samples of children with lower urinary tract infection
Table 2 Measure of agreement between resistance of antibiotics and presence of ESBL genes by cross tabulation Kappa statistics
Antibiotic Number of resistance / Kappa significant value
TEM SHV CTXM-G1 CTXM-G2 CTXM-G8 CTXM-G9
Piperacillin/Tazobactam 11/0.186 11/0.253 11/0.5 11/0.003 11/0.634 11/0.328
Ciprofloxacin 40/0.06 40/0.654 40/0.401 40/0.2 40/0.9 40/0.9
Nitrofurantoin 12/0.021 12/0.000 12/0.825 12/0.7 12/0.074 12/0.3
Gentamicin 28/0.2 28/0.843 28/0.08 28/0.4 12/404 12/0.9
Trimethoprim/Sulfamethoxazole 67/0.02 67/0.727 67/0.2 67/0.08 67/0.75 67/0.396
Cefoxitin 11/0.180 11/0.538 11/0.7 11/0.057 11/0.057 11/0.8
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age from 0 to 5 years (70.7%), wherecolonization with E.
coli and enterococci is known to diminish after 5 years
of age [26].
Molecular genotyping of ESBL-positive isolates
showed that the highest resistance was due to the pres-
ence of bla CTX-M genes (59%), particularly bla
CTX-MG1 (89.2%). bla TEM and bla SHV genes contrib-
uted to only 2.7 and 0.9% of ESBL resistance, which is
consistent with previous reports from the region and
around the globe [15, 28–31]. The high occurrence of bla
CTX-MG1 gene among pediatric population suggests
high dynamic transmission-ability of the plasmid-carried
gene, that contributes to the dissemination of CTX-M
enzymes to the community and could cause extra hori-
zontal transmission in healthcare facilities [32]. In busy
health care facilities, especially in developing countries,
the rapid turnover of patients to accommodate multiple
patients’ treatment could lead to breaching of infection
control measures, such as compliance with hand hy-
giene, which could lead to this horizontal transmission
of resistant bacteria from one patient to another. Unfor-
tunately, we could not compare our findings to others
from the region due to the scarcity of published data.
However, it has been globally reported that the predom-
inant genotype of ESBL-producing E. coli and K. pneu-
monia has changed from TEM and/or SHV to
CTX-M-1 since 2006 [33, 34], which seems to be the
trend in Qatar. Interestingly, our results indicated that
three bla genes (blaSHV, blaTEM and blaCTX-MG1/
blaCTX-MG9) were concurrently detected in 77% of K.
pneoumoniae isolates, whereas only 6.3% of the E. coli
isolates had combinations of the three genes (Fig. 3). On
the other hand, two out of seven bla genes were simul-
taneously detected in 18.2 and 3.2% of E. coli and K.
pneumonia, respectively. These results indicate different
genotypic profile of ESBL resistance between E. coli and
K. pneumoniae in urine samples which might indicate a
high transfer of genes among K. pneumoniae than E.
coli. Concerning the cephalosporins, all ESBL-producing
isolates showed 100% resistance to ampicillin, cephalo-
thin, cefazolin, ceftriaxone and 97.3% resistance to cefe-
pime. This finding coincided with a study carried in
intensive care unit (ICU) among adult patients at HMC,
Qatar, on respiratory tract and blood samples [35]. No
resistance in ESBL-producing isolates were observed
against amikacin, ertapenem, meropenem and imipe-
nem. Among the β-lactam/β-lactamase inhibitor combi-
nations, 10% were resistant to piperacillin/tazobactam,
whereas 99.1% were resistant to amoxicillin/clavulanic
acid. The clinical isolates presented 24.5% resistance to
gentamicin compared with 100% susceptibility to amika-
cin among aminoglycosides. Similarly, these findings
concur with the findings from the aforementioned study
in ICU patients, [35] with an exception of piperacillin/
tazobactam resistance which was reported at 22% in
ICU adult patients compared to 10% in pediatrics with
UTI. Resistance to piperacillin/tazobactam and cipro-
floxacin were significantly lower in our study (10 and
36.4% respectively) compared with another one from
Kingdom Saud Arabia (KSA) in a hospital at
Dammam-Eastern province, where resistance
reached63.2 and 84.6%, respectively [30]. Authors attrib-
uted high resistance to these antibiotics due to the mis-
use of ciprofloxacin and restriction of aminoglycosides
among adult in Dammam hospital. Whereas, ciprofloxa-
cin is restricted for use among adult patients at HMC
Fig. 4 Agglomerative hierarchical algorithm illustrating the similarity
of E. coli (a) and K. pneumoniae (b) based on the presence and
absence of ESBL genes, using past software version, 1.91 and
Jaccard’s coefficient. A similarity value = 0 indicates dissimilarity
between organisms, while similarity value of 1 means the organisms
are identical or very close to each other
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and very rarely used in pediatric population (personal
communication, 2017).
The resistance to oral antibiotics namely, nitrofuran-
toin, trimethoprim/sulfamethoxazole and ciprofloxacin
was found to be 9.1, 60.9 and 36.4%, respectively. Ob-
tained results were comparable to those observed in the
Middle East region [27], which indicate rapid dissemin-
ation of multidrug resistance bacteria in the communi-
ties [15, 36]. Worldwide, previous studies have reported
higher prevalence of ESBL resistance in Europe com-
pared to United States (US), but lower than South
America and Asia [37]. Our results indicate that the pat-
terns of ESBL resistance in Qatar, at least in pediatric
population, is more similar to Asia. It is worth noting
that 80% of population in Qatar is expatriates; arriving
mostly from countries in South East Asia. This could
partially explain our findings. Cumulatively, our findings
mandates the establishment of the antimicrobial stew-
ardship program and formulation of guidelines for em-
pirical use of prescription of antibiotics for UTI
infections among pediatric population.
We found that the majority of ESBL (156, 77.6%) pro-
ducers were multidrug resistant (resistant to 3 or more
different classes of antibiotics), with the most common
resistance pattern being to amoxicillin-clavulanate,
ampicillin, ciprofloxacin, Sulfamethoxazole/trimetho-
prim in addition to cephalosporines. Plasmids encoding
ESBL resistance often carry multiple genes conferring
multiple resistance, thus simultaneous resistance to
fluoroquinolones, aminoglycosides, tetracyclines, and tri-
methoprim sulfamethoxazole [12]. Our study revealed a
significant association (p < 0.05) between the presence of
TEM, nitrofurantoin and trimethoprim/sulfamethoxa-
zole; SHV and nitrofurantoin; CTXM-G2 and piperacil-
lin/tazobactam resistance. Thus, in our study, the use of
extended-spectrum cephalosporins, ciprofloxacin, ami-
noglycosides (gentamicin) and trimethoprim/sulfameth-
oxazole is compromised, leaving carbapenems as the
therapeutic option for severe infections caused by ESBL
producers. In agreement with our findings, [38] found
that plasmid-mediated quinolone resistance has been as-
sociated with bla CTX-M genes, where genes conferring
resistance to aminoglycosides and tetracycline and other
bla genes have been found on the same plasmids as the
bla CTXM [39]. Isolates in this study were all from
pediatric patients in the community who attended emer-
gency setting This highlights the therapeutic challenges
posed by ESBL producers, particularly in the UTI treat-
ment of community-onset [40].
Using seven genes to run agglomerative hierarchical
algorithm analysis [21–24] our study revealed eleven
clonal clusters among the 94 tested E. coli isolates. Clon-
ally related strains of cluster A2 were responsible for the
predominant UTI in pediatrics population 67.1% (58/
94), which produce only CTXM-G1 type enzyme,
followed by A5 (20.2%), which produce a combination of
TEM and CTXM-G1type enzymes. Five clonal clusters
were detected among K. pneumoniae with the main
cluster B2 producing concurrently a combination of
three enzyme types SHV, TEM and CTXM-G1. Whole
plasmid sequencing for representative isolates from each
cluster can be very helpful to better understand the re-
latedness and typing differences between the clusters
and elucidating further information on the mechanism
of resistance in these isolates. Unfortunately, similar mo-
lecular analysis of ESBL bacteria are lacking in the sur-
rounding country. This limit our understanding of the
trends and distribution of the strains, noting that more
than 80% of Qatari population are expats that arrive
from MENA region and South East Asia.
Conclusions
Although ESBL-producing members of Enterobacteria-
ceae have been reported in all Arabian Gulf region, very
limited data is available about the genetic makeup en-
coding for such resistance. This is the first study among
pediatric population in the state of Qatar that demon-
strate the correlation between genetic and phenotypic
profile of ESBL producing Enterobacteriaceae. The study
highlights an escalated problem of ESBL resistance in
Enterobacteriaceae causing UTI in pediatric population
in Qatar. Resistance was predominantly mediated by
CTX-MG1-type enzymes. The use of cephalosporins,
aminoglycosides (gentamicin) and trimethoprim/sulfa-
methoxazole is compromised in Qatar among pediatric
population with UTI, leaving carbapenems and amikacin
as the therapeutic option for severe infections caused by
ESBL producers. The negative impact of extensive use of
carpabenemes could lead to carbapenamase resistant En-
terobacteriaceae. This mandates further epidemiological
studies and implementation of regulatory programs to
reduce spread of ESBL producing Enterobacteriaceae in
the community. Further next generation sequencing
(NGS) studies are necessary for a more comprehensive
analysis of ESBL variants.
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